Welcome to our dedicated page for ALT5 Sigma Corporation SEC filings (Ticker: ALTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALT5 Sigma Corporation (NASDAQ: ALTS) files a range of reports with the U.S. Securities and Exchange Commission that document its fintech operations, digital asset treasury strategy, governance changes, and financial reporting status. On this page, investors can review ALT5’s Forms 10-K and 10-Q, along with current reports on Form 8-K and other disclosures, with AI-powered summaries that help explain key points from each filing.
ALT5’s periodic reports, such as the Form 10-K annual report and Form 10-Q quarterly reports, provide detail on its Fintech & Payments segment, $WLFI Treasury segment, and legacy biotech business. These filings describe how the company presents its digital asset payments, trading, and settlement infrastructure, as well as its holdings of $WLFI tokens and exposure to the USD1 stablecoin ecosystem. They also include discussions of risk factors, accounting policies, and segment information relevant to understanding ALTS as a fintech and digital asset-focused issuer.
The company’s Form 8-K filings offer timely updates on material events. Recent 8-Ks have covered topics such as changes in executive leadership, appointment of a new independent registered public accounting firm, Nasdaq filing delays and related communications, settlements of litigation involving unauthorized access to company information, and stockholder votes to increase authorized share capital. These reports provide context on corporate governance, control environment, and significant legal or strategic developments.
Through this SEC filings page, users can access real-time updates from EDGAR, including Form 4 insider transaction reports when available, and use AI-generated insights to quickly understand lengthy documents like 10-Ks and 10-Qs. This helps investors analyze how ALT5 manages its digital asset treasury, reports on its payments and settlement platforms, and addresses regulatory and governance matters that appear in its official filings.
David C. Danziger, a director of ALT5 Sigma Corp (ALTS), filed an Initial Statement of Beneficial Ownership (Form 3) dated
ALT5 Sigma Corporation is updating investors on its previously announced plan to separate into two companies and finance Alyea Therapeutics Corporation independently. A planned spin-off or similar transaction of Alyea will not take place using the earlier disclosed June 2, 2025 record date and may not occur under the previously communicated timeline. The Company states that, if it proceeds with a spin-off or similar transaction, it will later announce details such as a new record date, structure, and timing. ALT5 Sigma highlights its continued confidence in Alyea’s non-addictive pain treatment patents and potential progression to the next stage of clinical trials, and notes that it is continuing to evaluate strategic options to maximize and realize Alyea’s value.
ALT5 Sigma Corporation is soliciting shareholder votes on four proposals tied to a Private Placement that gives the Lead Investor the right to appoint a second director to the board. The board recommends shareholders vote FOR the Issuance, Appointment, Authorized Shares and Adjournment proposals. The filing shows ExodusPoint Capital Management, LP holds 5,856,700 shares, representing